Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
Mizrahi AG, Hamad H, Gugenheim A, Nisman B, Kuznetz A, David IB, Gelfend Y, Cohen S, Zick A, Sheva K, Nechushtan H, Peretz T, Meirovitz A.
Mizrahi AG, et al. Among authors: sheva k.
Anticancer Res. 2022 Nov;42(11):5257-5263. doi: 10.21873/anticanres.16032.
Anticancer Res. 2022.
PMID: 36288893